Art. -Nr.: HY-N1485

Cycloastragenol

(Synonyms: Astramembrangenin; Cyclosieversigenin)

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 78574-94-4
Formel: C₃₀H₅₀O₅
Molecular Weight:490.72

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Cycloastragenol Chemical Structure

CAS. Nr.: 78574-94-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	1.542 μM Compound: 8	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
DU-145	IC₅₀	7.258 μM Compound: 8	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
HEK293	IC₅₀	127.7 μM Compound: 8	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
HeLa	IC₅₀	2.198 μM Compound: 8	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
MCF7	IC₅₀	1.778 μM Compound: 8	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]

In Vitro

Cycloastragenol (0.03-3 μM; 24-72 hours) promotes viability, osteoblastic differentiation, and mineralization in MC3T3-E1 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cycloastragenol (5, 10, 20 mg/kg) is injected intraperitoneally at the onset of reperfusion, 12 h later and then twice daily for up to three days. Cycloastragenol dose-dependently reduces brain infarct volume, significantly ameliorated functional deficits, and prevents neuronal cell loss in middle cerebral artery occlusion (MCAO) mice. Cycloastragenol suppresses the mRNA expression of pro-inflammatory cytokines, including TNF-α and IL-1β, and inhibits the activation of microglia and astrocytes in the ischemic brain^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 78574-94-4
Appearance Solid
Molecular Weight 490.72
Formel C₃₀H₅₀O₅
Color White to off-white
SMILES

CC1(C)[C@@H](O)CC[C@]2(C3)[C@]43CC[C@]5(C)[C@@H]([C@](C)(O6)CC[C@H]6C(C)(O)C)[C@@H](O)C[C@](C)5[C@]4([H])C[C@H](O)[C@@]12[H]
Synonyms

Astramembrangenin; Cyclosieversigenin
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (9)

All In Vivo Efficacy StudyIFWB

Sort by:

Journal Impact Factor

Phytother Res

Cycloastragenol Alleviates Bone Cancer Pain by Targeting Sirt1 to Inhibit Neuronal Ferroptosis and Promote M2 Microglial Polarization in the Spinal Dorsal Horn of Rats. [Abstract]

2026 Apr;40(4):1626-1641. PMID: 41601212

Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]

Cycloastragenol (CAG; 20, 100, 500 μg/kg; Intrathecal injection) dose- dependently improved paw withdrawal threshold (PWT) in Bone cancer pain (BCP) rats.

Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]

Dose–response relationship of Cycloastragenol (CAG; 125, 250, 375, 500 μg/kg) showed increased antinociceptive effects with higher doses.

Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]

Cycloastragenol (CAG; 20, 100, 500 μg/kg; Intrathecal injection) significantly and dose-dependently reduced the Iba-1 expression, with thestrongest inhibition observed at 500 μg/kg in spinal dorsal horn of Bone cancer pain (BCP) rats.

Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]

Cycloastragenol (CAG; 20, 100, 500 μg/kg; Intrathecal injection) significantly decreased in Iba-1 protein levels in Bone cancer pain (BCP) rats.

Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]

Cycloastragenol (CAG; 20, 100, 500 μg/kg; Intrathecal injection) didnot significantly alter GFAP levels at any dose in spinal dorsal horn of Bone cancer pain (BCP) rats.
Int J Mol Sci

Cycloastragenol Improves Fatty Acid Metabolism Through NHR-49/FAT-7 Suppression and Potent AAK-2 Activation in Caenorhabditis elegans Obesity Model. [Abstract]

2026 Jan 13;27(2):772. PMID: 41596421
Int J Mol Sci

Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice. [Abstract]

2023 Mar 31;24(7):6554. PMID: 37047529

Cycloastragenol purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Mar 31;24(7):6554. [Abstract]

Cycloastragenol (CAG; 50,100 μM; 48 h) decreases the expression of PAI-1 and p21 in HELF cells.
Int J Mol Sci

Heat-Killed Staphylococcus aureus Induces Bone Mass Loss through Telomere Erosion. [Abstract]

2023 Feb 6;24(4):3179. PMID: 36834587
J Integr Med

Cycloastragenol induces apoptosis and protective autophagy through AMPK/ULK1/mTOR axis in human non-small cell lung cancer cell lines. [Abstract]

2024 Jul;22(4):503-514. PMID: 38849220
Sci Rep

Cycloastragenol attenuates osteoarthritis by restoring chondrocyte senescence via the NRF2/NF-κB signaling axis. [Abstract]

2026 Mar 12;16(1):13203. PMID: 41813816
J Cell Mol Med

Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial-Mesenchymal Transition and the PI3K Signalling Pathway. [Abstract]

2026 Apr;30(8):e71128. PMID: 41989454
Brain Res Bull

Cycloastragenol protected hippocampal CA1 neurons by regulating redox homeostasis and alleviated cognitive impairment following cerebral ischemia-reperfusion. [Abstract]

2026 Jan:234:111689. PMID: 41407128
Toxicol Appl Pharmacol

TERT transcription and translocation into mitochondria regulate benzo[a]pyrene/BPDE-induced senescence and mitochondrial damage in mouse spermatocytes. [Abstract]

2023 Sep 15:475:116656. PMID: 37579952

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 66.67 mg/mL (135.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0378 mL

10.1891 mL

20.3782 mL

5 mM

0.4076 mL

2.0378 mL

4.0756 mL

10 mM

0.2038 mL

1.0189 mL

2.0378 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yu Y, et al. Cycloastragenol: An exciting novel candidate for age-associated diseases. Exp Ther Med. 2018;16(3):2175-2182. [Content Brief]

[2]. Li M, et al. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin. 2020;41(8):1025-1032. [Content Brief]

[3]. Yu Y, et al. Cycloastragenol prevents age-related bone loss: Evidence in d-galactose-treated and aged rats. Biomed Pharmacother. 2020;128:110304. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0378 mL	10.1891 mL	20.3782 mL	50.9455 mL
	5 mM	0.4076 mL	2.0378 mL	4.0756 mL	10.1891 mL
	10 mM	0.2038 mL	1.0189 mL	2.0378 mL	5.0946 mL
	15 mM	0.1359 mL	0.6793 mL	1.3585 mL	3.3964 mL
	20 mM	0.1019 mL	0.5095 mL	1.0189 mL	2.5473 mL
	25 mM	0.0815 mL	0.4076 mL	0.8151 mL	2.0378 mL
	30 mM	0.0679 mL	0.3396 mL	0.6793 mL	1.6982 mL
	40 mM	0.0509 mL	0.2547 mL	0.5095 mL	1.2736 mL
	50 mM	0.0408 mL	0.2038 mL	0.4076 mL	1.0189 mL
	60 mM	0.0340 mL	0.1698 mL	0.3396 mL	0.8491 mL
	80 mM	0.0255 mL	0.1274 mL	0.2547 mL	0.6368 mL
	100 mM	0.0204 mL	0.1019 mL	0.2038 mL	0.5095 mL

Keywords

Cycloastragenol

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Cycloastragenol

Macrocyclic Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Aging Natural Product Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Cycloastragenol

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Cycloastragenol Related Classifications

HY-N1485 Related Classifications